Catalog Home Page

The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation

Fabre, M.A., Jones, D.C., Bunce, M., Morris, P.J., Friend, P.J., Welsh, K.I. and Marshall, S.E. (2004) The impact of thiopurine S-methyltransferase polymorphisms on azathioprine dose 1 year after renal transplantation. Transplant International, 17 (9). pp. 531-539.

Link to Published Version: http://dx.doi.org/10.1111/j.1432-2277.2004.tb00483...
*Subscription may be required

Abstract

Azathioprine metabolism is influenced by activity of the enzyme thiopurine S-methyltransferase (TPMT), which varies markedly between individuals. In this study we examined the influence of TPMT gene polymorphisms on azathioprine dose 1 year after renal transplantation. TPMT coding and promoter genotypes were determined using PCR-based assays. Azathioprine dose, white cell count, and intercurrent events throughout the first year after renal transplantation were ascertained from contemporaneous clinical notes. All patients analysed (n = 172) received an initial azathioprine dose of 1.5 mg/kg per day. Twelve individuals with one variant TPMT coding allele were detected (*3A n = 11, *3C n = 1). Of these, 58% required azathioprine dose reduction because of leucopenia, compared to only 30% of homozygous wild-type patients (P = 0.04). A significant correlation between the presence of ≥11 variable number tandem repeats (VNTRs) in the TPMT promoter and reduction in azathioprine dose was also identified (P = 0.001). We concluded that when azathioprine is administered at an initial dose of 1.5 mg/kg per day, both coding and promoter TPMT polymorphisms influence the dose tolerated.

Publication Type: Journal Article
Publisher: Springer-Verlag
Copyright: © 2004 Springer-Verlag
URI: http://researchrepository.murdoch.edu.au/id/eprint/5151
Item Control Page